NCT00618371View on ClinicalTrials.gov

Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
HIV Infection
Interventions
DRUG

Raltegravir (MK-0518)

Antiretroviral drug intensification with Raltegravir (MK0518) 400mg orally every 12 hours for 28 days in addition to the prescribed antiretroviral therapy

Trial Locations (1)

15213

University of Pittsburgh, Pittsburgh

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Pittsburgh

OTHER

NCT00618371 - Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia | Biotech Hunter | Biotech Hunter